image: Insilico Medicine Founder & CEO Alex Zhavoronkov, PhD, will address the digital transformation of pharma and biotech. view more
Credit: Insilico Medicine
Alex Zhavoronkov, PhD, founder and CEO of clinical stage artificial intelligence (AI)-driven drug discovery company Insilico Medicine, will discuss “Driving Digital Transformation in Pharma and Biotech” at the inaugural Financial Times Health Technology Summit happening virtually on Thursday, Dec. 1.
Along with Cristina Durán, Chief Digital Health Officer in R&D at AstraZeneca, Zhavoronkov will talk about the ways that technology and AI are transforming traditional drug discovery, evolving the pharma value chain, aiding the discovery and development of novel targets and therapeutics, and impacting the pharma workforce. The panel will be moderated by Hannah Kuchler, Global Pharmaceuticals Correspondent for Financial Times. The panel discussion is happening at 1:35pm GMT. Other discussions will focus on digital surgery, health technology innovators, technology for mental health, the investment landscape for health technology, and closing the digital health divide.
“A few years ago, many debated the value of modern AI for drug discovery,” says Zhavoronkov. “But since 2020, Insilico has used its Pharma.AI platform to build a pipeline of promising therapeutic programs, nominated eight preclinical candidates, and entered human clinical trials with an AI-discovered target and AI-designed molecule for a broad, age-related chronic disease. We also saw significant improvements in speed and probability of success achieved by our pharma partners. We will soon integrate AI-driven robotics, novel computational tools, and new algorithms to accelerate the process even further.”
Just recently, Insilico signed its largest pharma partnership deal to date, a strategic research collaboration with Sanofi worth up to $1.2B. The Company has also signed recent partnerships with EQRx and Fosun Pharma to use its AI tools to advance new therapeutics.
Insilico’s end-to-end Pharma.AI platform leverages a proprietary generative AI algorithm to discover novel targets (PandaOmics), design new therapeutics (Chemistry42), and predict the outcome of clinical trials (InClinico). The Company’s lead drug, for idiopathic pulmonary fibrosis, is currently in Phase 1 trials, the first AI-discovered and AI-designed drug to reach this milestone. There are 30 other programs in the Company’s internal pipeline for cancer, fibrosis, immunology, and COVID-19.
Since it was founded in 2014, Insilico Medicine has raised over $400m in funding from notable biotech and tech investors.
About Insilico Medicine
Insilico Medicine, a clinical stage end-to-end artificial intelligence (AI)-driven drug discovery company, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques to discover novel targets and to design novel molecular structures with desired properties. Insilico Medicine is delivering breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, and aging-related diseases. Headquartered in Hong Kong, Insilico Medicine has additional offices in New York, Montreal, Shanghai, Suzhou, Taipei, and Abu Dhabi. www.insilico.com
For media inquiries, contact media@insilicomedicine.com